Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer

Kalra, R; Chen, CH; Wang, JK; Bin Salam, A; Dobrolecki, LE; Lewis, A; Sallas, C; Yates, CC; Gutierrez, C; Karanam, B; Anurag, M; Lim, B; Ellis, MJ; Kavuri, SM

Kavuri, SM (通讯作者)，Baylor Coll Med, Lester & Sue Smith Breast Ctr, Dept Med, One Baylor Plaza, Houston, TX 77030 USA.;Ellis, MJ (通讯作者)，Baylor Coll Med, Lester & Sue Smith Breast Ctr, One Baylor Plaza, Houston, TX 77030 USA.

CANCER RESEARCH, 2022; 82 (16): 2928

Abstract

? The pan-HER tyrosine kinase inhibitor (TKI) neratinib is therapeutically active against metastatic breast cancers harboring activating HER2 mutation......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索